NCT07136220 A Pilot Study to Evaluate Equol and Its Effects on Menopausal Symptoms Experienced by Women in Singapore
| NCT ID | NCT07136220 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ang Seng Bin |
| Condition | Menopause |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-07-02 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this study is to evaluate the effect of equol on menopausal symptoms of women. Our hypothesis is that equol producers will have milder menopausal symptoms compared to non-equol producers. Equol is known as a metabolite produced by gut microbiota from soy-related diet and has estrogen-like activity compared to the isoflavones from soybean. Previous studies have shown that some women can produce equol from soy-related diet, but the others cannot because they don't have the bacteria which can metabolite daidzein in gut even if they take isoflavones thorough soybean products. This study will involve participants consuming a soy protein bar and collection of urine samples before and after its consumption.
Eligibility Criteria
Inclusion Criteria: \- Women aged 40-60 Exclusion Criteria: * Pregnant women * Allergy to Soy * Allergy to nuts * Consumed antibiotics within 7 days of the study * Has a history of autoimmune diseases * Has a history of thyroid disease * On medical treatment with hormone therapy, elective oestrogen receptors modulators * Consuming equol-containing supplements or food * Consuming painkillers * Consuming anti-depressants and/or sleeping pills
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07136220 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 60 Years, studying Menopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07136220 currently recruiting?
Yes, NCT07136220 is actively recruiting participants. Contact the research team at ang.seng.bin@singhealth.com.sg for enrollment information.
Where is the NCT07136220 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07136220 clinical trial?
NCT07136220 is sponsored by Ang Seng Bin. The trial plans to enroll 300 participants.